NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Prostate cancer drug darolutamide under Real-World microscope
Disease control OngoingThis study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Promising prostate cancer drug apalutamide tested in chinese patients
Disease control OngoingThis study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alo…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising drug may delay prostate cancer spread in High-Risk patients
Disease control OngoingThis study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug made available early for men with advanced prostate cancer
Disease control NO_LONGER_AVAILABLEThis study provides early access to apalutamide for men whose prostate cancer has stopped responding to standard hormone therapy but has not yet spread. The goal is to gather more safety information while offering treatment before the drug is widely available. Participants must c…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC